Skip Navigation LinksScientific ReferencesBifidum References

Scientific and Clinical Studies
Theralac® Probiotic Strains

Bifidobacterium lactis Bi-07 – Present in Theralac® at 3 billion CFU/capsule
 
References

Complimentary human strain synergistic with BL-34 – on deposit at the ATCC as SD5220.

1) Works in combination with LA-1 and BL-34 to reduce negative impact of antibiotics on
    G.I. flora: J. Med. Microbiol., 2009, Vol. 58, pp 663-670.

2) Bi-07 has been characterized as B. lactis using PCR:
    Appl. Environ. Microbiol., 2002, Vol. 68 (12), pp 6429-6434.

3) Bi-07 reduces intestinal inflammation and balances mucosal immune response:
    World J. Gastroenterology, 2007, Vol. 13 (2), pp 236-243.

4) Bi-07 reduces Candida colonization and severity of candidiasis:
    Infect. Immunol., 1997, Vol. 65, pp 4165-4172.

5) Bi-07 plus LA-1 decreased diarrhea in 120 children ages 12-36 mo. in a
    double-blind, placebo controlled study: Pediatric Research, 1999, Vol. 39 (2), p 104.

6) Bi-07 significantly reduced upper respiratory infection symptoms in a
    study involving 326 children: U.S. Provisional Patent Appl., 2006, No. 60/848,662.

Return to Scientific References